Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers
Rita Sulahian, Jason J. Kwon, Katherine H. Walsh, et al.
Cell Reports (2019) Vol. 29, Iss. 1, pp. 118-134.e8
Open Access | Times Cited: 79

Showing 1-25 of 79 citing articles:

RAS-targeted therapies: is the undruggable drugged?
Amanda R. Moore, Scott Rosenberg, Frank McCormick, et al.
Nature Reviews Drug Discovery (2020) Vol. 19, Iss. 8, pp. 533-552
Open Access | Times Cited: 819
KRAS mutation: from undruggable to druggable in cancer
Lamei Huang, Zhixing Guo, Fang Wang, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 600
Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma
Yunzhen Qian, Yitao Gong, Zhiyao Fan, et al.
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 250
Rational combinations of targeted cancer therapies: background, advances and challenges
Haojie Jin, Liqin Wang, René Bernards
Nature Reviews Drug Discovery (2022) Vol. 22, Iss. 3, pp. 213-234
Closed Access | Times Cited: 246
KRAS mutation in pancreatic cancer
Ji Luo
Seminars in Oncology (2021) Vol. 48, Iss. 1, pp. 10-18
Open Access | Times Cited: 223
Rapid and direct control of target protein levels with VHL-recruiting dTAG molecules
Behnam Nabet, Fleur M. Ferguson, Bo Kyung A. Seong, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 209
Scribble mis-localization induces adaptive resistance to KRAS G12C inhibitors through feedback activation of MAPK signaling mediated by YAP-induced MRAS
Yuta Adachi, Ryo Kimura, Kentaro Hirade, et al.
Nature Cancer (2023) Vol. 4, Iss. 6, pp. 829-843
Closed Access | Times Cited: 47
Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy
Suman Mukhopadhyay, Hsin‐Yi Huang, Ziyan Lin, et al.
Cancer Research (2023) Vol. 83, Iss. 24, pp. 4095-4111
Open Access | Times Cited: 43
Combinatorial strategies to target RAS-driven cancers
Naiara Perurena, Lisa Situ, Karen Cichowski
Nature reviews. Cancer (2024) Vol. 24, Iss. 5, pp. 316-337
Closed Access | Times Cited: 28
Integrating artificial intelligence in drug discovery and early drug development: a transformative approach
Alberto Ocaña, Atanasio Pandiella, Cristian Privat, et al.
Biomarker Research (2025) Vol. 13, Iss. 1
Open Access | Times Cited: 2
MEK inhibitor resistance mechanisms and recent developments in combination trials
Eucharist Kun, Yvonne T.M. Tsang, Chun Wai Ng, et al.
Cancer Treatment Reviews (2020) Vol. 92, pp. 102137-102137
Open Access | Times Cited: 129
SETD5-Coordinated Chromatin Reprogramming Regulates Adaptive Resistance to Targeted Pancreatic Cancer Therapy
Zhentian Wang, Simone Hausmann, Ruitu Lyu, et al.
Cancer Cell (2020) Vol. 37, Iss. 6, pp. 834-849.e13
Open Access | Times Cited: 75
shinyDepMap, a tool to identify targetable cancer genes and their functional connections from Cancer Dependency Map data
Kaoru Shimada, John A. Bachman, Jeremy Muhlich, et al.
eLife (2021) Vol. 10
Open Access | Times Cited: 67
Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
Daolin Tang, Guido Kroemer, Rui Kang
Molecular Cancer (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 63
Structure–function analysis of the SHOC2–MRAS–PP1C holophosphatase complex
Jason J. Kwon, Behnoush Hajian, Yuemin Bian, et al.
Nature (2022) Vol. 609, Iss. 7926, pp. 408-415
Open Access | Times Cited: 58
Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS
Guowei Yin, Jing Huang, Johnny Petela, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 31
Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development—a narrative review
Mariacarmela Santarpía, Giuliana Ciappina, Calogera Claudia Spagnolo, et al.
Translational Lung Cancer Research (2023) Vol. 12, Iss. 2, pp. 346-368
Open Access | Times Cited: 30
Signaling from RAS to RAF: The Molecules and Their Mechanisms
Hyesung Jeon, Emre Tkacik, Michael J. Eck
Annual Review of Biochemistry (2024) Vol. 93, Iss. 1, pp. 289-316
Closed Access | Times Cited: 12
The small GTPase MRAS is a broken switch
Gabriela Bernal Astrain, Regina Strakhova, Chang Hwa Jo, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 1
Genome-wide CRISPR-cas9 knockout screening identifies GRB7 as a driver for MEK inhibitor resistance in KRAS mutant colon cancer
Chune Yu, Dan Luo, Jing Yu, et al.
Oncogene (2021) Vol. 41, Iss. 2, pp. 191-203
Open Access | Times Cited: 55
Structure of the SHOC2–MRAS–PP1C complex provides insights into RAF activation and Noonan syndrome
Daniel A. Bonsor, Patrick Alexander, Kelly Snead, et al.
Nature Structural & Molecular Biology (2022) Vol. 29, Iss. 10, pp. 966-977
Open Access | Times Cited: 37
Structure of the MRAS–SHOC2–PP1C phosphatase complex
Zachary J. Hauseman, Michelle Fodor, Anxhela Dhembi, et al.
Nature (2022) Vol. 609, Iss. 7926, pp. 416-423
Open Access | Times Cited: 31
Systematic profiling of conditional degron tag technologies for target validation studies
Daniel P. Bondeson, Zachary Mullin-Bernstein, Sydney Oliver, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 31
Complex synthetic lethality in cancer
Colm J. Ryan, Lovely Paul Solomon Devakumar, Stephen J. Pettitt, et al.
Nature Genetics (2023) Vol. 55, Iss. 12, pp. 2039-2048
Closed Access | Times Cited: 21
Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance
Harish N. Vasudevan, Emily Payne, Cyrille L. Delley, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top